CTLA4 and cancer: Finally, since injection of anti–CTLA-4 antibodies can also promote IL-21 production (Wang et al., 2015), our findings may be relevant to autoimmune adverse events in cancer patients receiving checkpoint immunotherapy, where autoantibodies frequently emerge (Tahir et al., 2019; Ghosh et al., 2022).